Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30

$0.84+0.01 (+1.41%)

Close on Nov 13, 2026Market cap $289.76MP/E –Yield 0.00%

Allogene Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Allogene Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Allogene Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALLO.

Revenue growth-100.0% · median -41.1%

Advertisement
300 × 250

See a number that looks wrong?